Johnson & Johnson Reports Phase 3 MARIPOSA Results for Rybrevant Plus Lazertinib in NSCLC

Johnson & Johnson today announced results from the Phase 3 MARIPOSA trial evaluating amivantamab (Rybrevant) plus lazertinib versus osimertinib in patients with previously untreated EGFR-mutated non-small cell lung cancer. The trial met its primary endpoint, demonstrating a statistically significant improvement in progression-free survival for amivantamab plus lazertinib. The median PFS was 23.7 months for amivantamab plus lazertinib versus 16.6 months for osimertinib. These results support amivantamab plus lazertinib as a potential new first-line treatment option for EGFR-mutated NSCLC.